Platelet aggregation in response to ADP is highly variable in normal donors and patients on anti-platelet medication

Eimear Dunnehttp://orcid.org/0000-0001-9862-1398, Karl Egan, Siobhán McFadden, David Foley 3 , and Dermot Kenny
  • 1 Cardiovascular Biology and Clinical Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland
  • 2 Biomedical Diagnostics Institute, Dublin City University, Dublin, Ireland
  • 3 Cardiology, Beaumont Hospital, Dublin, Ireland
Eimear DunneORCID iD: http://orcid.org/0000-0001-9862-1398, Karl Egan, Siobhán McFadden, David Foley and Dermot Kenny

Abstract

Background: P2Y12 inhibitors are indicated in patients following percutaneous coronary intervention. Several studies have demonstrated that high on treatment platelet reactivity is correlated with outcomes yet prospective studies of guided therapy have failed to show benefit. There is a paucity of studies on the platelet aggregation response to ADP before P2Y12 therapy is started. The aim of this study was to characterize platelet responses to 20 μM ADP by light transmission aggregometry (LTA) in a homogenous population.

Methods: Platelet aggregation was assessed in 201 patients on dual antiplatelet therapy, 98 patients on aspirin alone and 47 normal, healthy volunteers free from anti-platelet medication.

Results: Consensus guidelines suggest that a platelet aggregation response in response to the agonist ADP of <57% is an adequate therapeutic response to P2Y12 inhibition. Seven healthy donors and 38 patients taking aspirin only had aggregation responses below 57%.

Conclusions: The results of our study demonstrate that 15% of normal donors and 38% of patients taking aspirin only would be classified as having a therapeutic response to P2Y12 inhibition using current guidelines.

  • 1.

    Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 2013;6:1111–28.

    • Crossref
    • PubMed
    • Export Citation
  • 2.

    Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013;6:854–63.

    • Crossref
    • PubMed
    • Export Citation
  • 3.

    Villacorta AS, Villacorta Junior H, Batista MJ, Gomes RV, Macedo LA, Helmuth B, et al. High on-treatment platelet reactivity predicts cardiac events in patients with drug-eluting stents. Arq Bras Cardiol 2013;100:221–8.

    • PubMed
    • Export Citation
  • 4.

    Cattaneo M. High on-treatment platelet reactivity–definition and measurement. Thromb Haemost 2013;109:792–8.

    • Crossref
    • PubMed
    • Export Citation
  • 5.

    Saia F, Marino M, Campo G, Valgimigli M, Guastaroba P, Taglieri N, et al. Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). Am J Cardiol 2013;112:792–8.

    • Crossref
    • PubMed
    • Export Citation
  • 6.

    Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005;115:89–94.

    • Crossref
    • PubMed
    • Export Citation
  • 7.

    Cattaneo M. Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel. J Cardiovasc Med 2013;14 Suppl 1:S16–21.

    • Crossref
    • Export Citation
  • 8.

    Sousa-Uva M, Storey R, Huber K, Falk V, Leite-Moreira AF, Amour J, et al. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J 2014;35:1510–4.

    • Crossref
    • PubMed
    • Export Citation
  • 9.

    Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004;43:979–84.

    • Crossref
    • PubMed
    • Export Citation
  • 10.

    Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009;53:667–77.

    • Crossref
    • PubMed
    • Export Citation
  • 11.

    Miller CH, Rice AS, Garrett K, Stein SF. Gender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results. Br J Haematol 2014;165:842–53.

    • Crossref
    • PubMed
    • Export Citation
  • 12.

    Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339–43.

    • Crossref
    • PubMed
    • Export Citation
  • 13.

    Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013;11:1183–9.

    • Crossref
    • Export Citation
  • 14.

    Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004;8:508–12.

    • Crossref
    • PubMed
    • Export Citation
  • 15.

    Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res 2011;128:e130–6.

    • Crossref
    • PubMed
    • Export Citation
  • 16.

    Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011;105:107–12.

    • Crossref
    • PubMed
    • Export Citation
  • 17.

    Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–62.

    • Crossref
    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Search